Clopidogrel bisulfate 97% CAS NO (120202-66-6) at cheap price

Chemical Identity: Clopidogrel Bisulfate (CAS No. 120202-66-6) Description: Clopidogrel bisulfate is the bisulfate salt form of clopidogrel, a thienopyridine derivative. It is an antiplatelet agent that inhibits platelet aggregation by selectively blocking the P2Y12 adenosine diphosphate (ADP) receptor on platelets.

Mechanism of Action:

• Clopidogrel bisulfate is a prodrug that requires metabolic activation by cytochrome P450 enzymes, primarily CYP2C19, to its active form.
• The active metabolite of clopidogrel irreversibly binds to the P2Y12 receptor on platelets, inhibiting ADP-induced platelet activation and subsequent platelet aggregation.
• By inhibiting platelet aggregation, clopidogrel bisulfate helps to prevent blood clot formation and reduces the risk of thrombotic events such as heart attack and stroke.

Indications:

• Clopidogrel bisulfate is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (ACS), including unstable angina, non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI).
• It is also used in patients with a history of myocardial infarction, ischemic stroke, peripheral arterial disease, or those undergoing percutaneous coronary intervention (PCI) with stenting.

Dosage Forms:

• Clopidogrel bisulfate is available in oral tablet form for administration. It is commonly supplied as 75 mg tablets for daily use.

Administration:

• The usual recommended dose of clopidogrel bisulfate is 75 mg once daily, taken orally with or without food.
• It is important to follow the prescribed dosage regimen and instructions provided by a healthcare professional.

Adverse Effects:

• Common adverse effects of clopidogrel bisulfate may include bleeding, bruising, gastrointestinal discomfort, and rash.
• Rare but serious adverse effects may include severe bleeding, thrombotic thrombocytopenic purpura (TTP), and neutropenia.

Drug Interactions:

• Clopidogrel bisulfate may interact with other medications that affect platelet function or metabolism, including proton pump inhibitors (PPIs), anticoagulants, and certain antidepressants.
• It is important to inform healthcare providers about all medications, including over-the-counter drugs and herbal supplements, before starting treatment with clopidogrel bisulfate.

Monitoring:

• Patients receiving clopidogrel bisulfate therapy may require monitoring of platelet function and blood counts, particularly in those at increased risk of bleeding or with comorbid conditions affecting hematological parameters.

Contraindications:

• Clopidogrel bisulfate is contraindicated in individuals with active pathological bleeding, severe liver disease, or hypersensitivity to clopidogrel or other thienopyridines.
• It should be used with caution in patients with a history of bleeding disorders or peptic ulcer disease.

Pregnancy and Lactation:

• The safety of clopidogrel bisulfate during pregnancy and lactation has not been established. It should be used only if the potential benefits outweigh the potential risks and under the guidance of a healthcare professional.